Anixa Biosciences CAR-T Co-Inventor to Present at South Carolina Clinical Research Retreat

Anixa Biosciences, Inc. (NASDAQ: ANIX) announced that Jose Conejo-Garcia, M.D., Ph.D., Professor of Immunology at Duke University School of Medicine and co-inventor of Anixa's CAR-T technology, will deliver a keynote presentation at the South Carolina Clinical & Translational Research Institute 2026 Retreat: Cell-Based Therapies from Discovery to Translation on March 6, 2026. His remarks are expected to include discussion of Anixa's ongoing Phase 1 clinical trial of liraltagene autoleucel, or lira-cel, an FSHR-targeted CAR-T therapy for recurrent ovarian cancer first discovered at The Wistar Institute, with the study enrolling women who have progressed after at least two prior therapies.

Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system.

The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit https://www.anixa.com.

The announcement matters because it highlights the continued advancement of Anixa's novel cancer immunotherapy platform at a major clinical research forum. The presentation by Dr. Conejo-Garcia, who co-invented the underlying technology, provides validation and scientific credibility to Anixa's approach. The focus on the Phase 1 trial of lira-cel for recurrent ovarian cancer is particularly significant as this patient population has limited treatment options after multiple prior therapies fail. The CER-T technology represents a differentiated approach in the competitive CAR-T field, potentially offering advantages in targeting and efficacy. Anixa's collaborative model with leading institutions like Moffitt Cancer Center and Cleveland Clinic strengthens its research pipeline and commercialization potential across multiple cancer types. The keynote at the SCTR 2026 Retreat positions Anixa's work within the broader context of translating cell-based therapies from discovery to clinical application, signaling its progress toward addressing unmet needs in oncology.